Navigation Links
Tengion to Present at 27th Annual JP Morgan Healthcare Conference
Date:1/6/2009

Completed Phase 2 Bladder Augment Trial and Plans for Registration Trial to be Discussed

Breakthrough in Kidney Regeneration Program: Preclinical Progress to be Highlighted

EAST NORRITON, Pa., Jan. 6 /PRNewswire/ -- Tengion Inc., a clinical-stage organ regeneration company with products in urologic, vascular, and renal regeneration, today announced that Steven Nichtberger, M.D., president and chief executive officer, is scheduled to present at the 27th Annual JP Morgan Healthcare Conference on Monday, January 12, 2009 at 2:30 p.m. PST. The conference will be held January 12 - 15 at The Westin St. Francis Hotel in San Francisco.

For the first time, Dr. Nichtberger will discuss Tengion's completion of its Phase 2 clinical trial in patients with neurogenic bladder due to spina bifida and the company's plans for a Phase 3 trial of its Tengion Neo-Bladder Augment(R) in patients with neurogenic bladder, planned for initiation in the first half of 2009. Dr. Nichtberger will also present breakthrough preclinical data from Tengion's renal program.

"Regenerative medicine is on the verge of unimagined breakthroughs. Similar to the emergence of novel chemical, protein, and antibody therapeutics in the past few decades, the impact of regenerative medicine on human health is emerging with great promise in the new millennium," said Dr. Nichtberger. "Tengion is at the forefront of this space with a practical and proven organ regeneration technology platform with nearly a decade of human clinical experience. Recent preclinical advances in our renal program, which is focused on eliminating the need for dialysis in patients with emerging kidney failure, reinforce the promise and value of our technology platform. The past year has been filled with important milestones that position us well for 2009."

"Kidney regeneration from patients' own cells would become the standard of care for chronic renal failure therapy. Tengion's work on the neo-kidney is an important early step towards this goal," said Brian Pereira, MD, former President of the National Kidney Foundation, editor of the leading textbook, "Chronic Kidney Disease, Dialysis, & Transplantation," and Board member of Tengion, Inc.

About Tengion

Tengion is a clinical-stage organ regeneration company with products in urologic, vascular and renal regeneration based on its proprietary Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create neo-organs or neo-tissues that are designed to catalyze the body's innate ability to regenerate. Tengion is a fully-integrated organization, with scalable U.S. and European manufacturing and distribution capabilities, experienced research, development, clinical and commercial teams, and significant intellectual property. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information, please visit www.tengion.com.


'/>"/>
SOURCE Tengion
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
4. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
5. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
6. AtriCure to Present at Roth Capital Partners 2007 New York Conference
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. MDS to Present at Thomas Weisel Partners Healthcare Conference
9. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
10. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... San Francisco, CA (PRWEB) , ... January 19, 2017 , ... ... and financial planning assistance to commercial and residential clients in the California Bay Area, ... promote positive heart health in the region. , Heart disease is the primary killer ...
(Date:1/19/2017)... ... 19, 2017 , ... Attorney Robert “RC” Pate , founder of The ... the Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric ... firsthand the effect of the critical funding gap for research into pediatric cancer research. ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Connecticut Dermatology Group ... Kim, a highly experienced and compassionate dermatologist. Dr. Kim brings an extensive background ... , “It is with considerable pleasure to welcome back Dr. Kim to the CDG ...
(Date:1/19/2017)... ... 19, 2017 , ... Each year, the Southeastern Society of ... hundreds of surgeons from over fifteen different countries come together to share and ... augmentation to breast reconstruction for breast cancer patients, teaching these surgical techniques ...
(Date:1/18/2017)... ... 2017 , ... From a health perspective, 2017 will clearly be the Year ... chronic disease, mental health and general physical well-being. The New York Times suggested a ... , For one Charlottesville restaurant, good gut health is clearly on the menu. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 ... administration appears serious about reducing the FDA,s regulatory ... innovation in the medical drug industry, many of ... with new clinical trials and development of advanced ... forging ahead with recent developments include:  Moleculin Biotech, ...
(Date:1/19/2017)... 2017  ViewRay, Inc. (Nasdaq: VRAY ... clinical MRI-guided radiation therapy system, announced today that it ... million through a private placement of its common ... financing and was joined by certain of ViewRay,s ... Venture Partners, and an additional new institutional investor, ...
(Date:1/19/2017)... ROCKVILLE, Md. , Jan. 18, 2017 /PRNewswire/ ... a late-stage clinical company developing therapeutics designed to ... health of patients, today confirmed plans to initiate ... the Company,s modified-release reformulation of lovastatin lactone designed ... M. smithii) in the gut to treat ...
Breaking Medicine Technology: